Hearing Loss in Chronic Kidney Disease by Antwi, Sampson & Issahalq, Mohammed Duah
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Hearing Loss in Chronic Kidney 
Disease
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Abstract
Chronic kidney disease (CKD) is assuming public health significance worldwide 
largely driven by the surge in diabetes mellitus, hypertension and obesity. CKD 
patients, particularly those from resource restraint regions of the world, face huge 
challenge in terms of accessibility and affordability to care. Besides these challenges 
in care, several other co-morbidities often exist among these patients in addition to 
the primary disease like diabetes and hypertension. Yet, these “subtle” co-morbidities 
are often overlooked by Caregivers. Hearing loss is one of such co-morbidities CKD 
patients face but it is often overlooked. The situation is worse among children who 
often cannot express themselves. The etiology of hearing loss among CKD patients are 
multifactorial. It is hoped that this neglected aspect of care for patients with chronic 
kidney disease will receive the needed attention for holistic care of the CKD patient.
Keywords: chronic kidney disease, co-morbidity, hearing loss, aetiopathogenesis, 
Oto-renal syndrome
1. Introduction
1.1 Structure and function of the ear
The ear is the organ for hearing. The human ear consists of three parts: 1. the 
external ear 2. the middle ear 3. the inner ear. The inner ear, also called the laby-
rinth, consists of the vestibular apparatus for balance; and the cochlear for hearing.
The external and middle ear portions of this hearing apparatus are responsible 
for conducting sound energy from the exterior and transforming it into mechanical 
energy towards the inner ear. The inner ear then converts the received mechani-
cal energy into electrical energy. The cochlear component of the inner ear is the 
end-organ for hearing. The organ of Corti within the cochlear is the functional 
processing unit for hearing aspect of the inner ear. This organ is very sensitive to the 
chemical environment. Changes in the physiological environment of the organ of 
Corti cause toxic damage to it (ototoxicity).
Variety of factors contribute to functional deterioration of the inner ear. These 
include aging, chemicals, medications and certain diseases both congenital and 
acquired [1].
1.2 The kidney and the inner ear (labyrinth)
The kidney is the organ primarily responsible for the elimination of toxic 
metabolites from the body and thereby creating the required milieu for the internal 
organs, including the inner ear, to function optimally.
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Diseases of the kidney have detrimental effect on the inner ear, not only because 
of buildup of metabolic toxins in the blood to affect the functions of the labyrinth, 
but also the fact that the functional unit of the kidney, the nephron, has structural 
and functional similarities with the stria vascularis in the labyrinth [2, 3]. These 
similarities make both organs vulnerable to similar agents and genetic disruptions 
in utero [2, 3].
1.2.1 Ion channels and transporters expressed in both the inner ear and kidney
ClC proteins are a large family of proteins that mediate voltage-dependent trans-
port of Cl − ions across cell membranes [4]. They are controlled by the CLC gene 
family. They comprise the CLC-K channels, Cl − channels and Cl−/H+ antiporters. 
A critical subunit of the CLC-K channels is the protein barttin. These channels and 
transporters are expressed in both the inner ear and the kidney. [4–6] (Figure 1).
The CLC-K channels form homodimers which additionally co-assemble with 
the small protein barttin. ClC-K/barttin localizes at the basolateral membranes 
of both the thin and thick ascending limbs of Henle’s loop, and in marginal cells 
of the stria vascularis of the inner ear [5]. In the kidney, they are involved in 
NaCl reabsorption; in the inner ear they are important for endolymph production 
(see 2.1.1.3 below).
2. Hearing loss in chronic kidney diseases
The kidney and the inner ear both suffer from the adverse effects of diseases like 
diabetes mellitus, hypertension and aging.
Figure 1. 
ClC-K channels are expressed in kidney and inner ear. (A) At the nephrons, luminal NKCC2 transporters 
build up Na+, K+ and Cl− into the cells. K+ flows back to the lumen through ROMK1 channels; Na+ and Cl− are 
reabsorbed to the bloodstream separately through Na+/K+ ATPase and ClC-kb channels, respectively. (B) In 
the Stria Vascularis, Na+, K+ and Cl− are transported into the cells by basolateral NKCC1 transporters. Na+ 
and Cl− are recycled back to the interstitium by Na+/K+ ATPase and both ClC-Ks isomers, respectively. K+ 
flows through KCNQ1/KCNE1 channels and accumulates into the endolymph, a condition required for sensory 
transduction in inner hair cells. Figure courtesy Poroca DR et al. [4].
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Several reports have indicated that hearing loss is more prevalent among CKD 
patients than the general population in different parts of the world. [7–11] In a Korean 
study by Seo1 JY et al. involving 5,226 participants ≥19 years of age whose estimated 
glomerular filtration rate (eGFR) and hearing threshold were measured, the authors 
found the odds of hearing impairment to be 1.25 times higher (95% confidence inter-
val: 1.12–1.64, p-value <0.001) in participants with an eGFR <60 mL/min/1.73 m2 
(chronic renal failure group) than in those with an eGFR ≥60 mL/min/1.73 m2 
(normal or mildly impaired renal function group) after adjustments for age, sex, 
smoking, alcohol, body mass index, diabetes mellitus, hypertension, dyslipidemia, 
and microalbuminuria [7]. Among the risk parameters of CKD associated with hear-
ing impairment, linear regression analysis adjusted for age and sex determined that 
each increase of serum creatinine or blood pressure was positively associated with an 
increase in hearing threshold (p-value <0.01) [7].
2.1 Etiology of hearing loss among patients with chronic kidney disease
The causes of hearing loss among patients with chronic kidney disease are 
multifactorial, ranging from genetics through uraemic complications to medication 
side effects [9, 12–14].
2.1.1 Genetic causes
2.1.1.1 Hereditary nephritis
Hereditary nephritis (Alport’s syndrome) is a recognized cause of CKD among 
adolescents and young adults. Alport’s syndrome is characterized by progressive kidney 
failure (mainly from second decade), sensorineural hearing loss and characteristic ocu-
lar findings. Cecil Alport first described the disease as hereditary haematuric nephritis 
with hearing loss in a family whose affected males died in adolescence [15]. The disease is 
caused by a defect in the gene that codes for basement membrane type IV collagen [15]. 
The consequence of this genetic defect is a thickened and often split basement mem-
brane giving a characteristic “basket weave” pattern. The disease has variable pattern of 
inheritance but 85% of cases are X-linked and most or all of those results from mutation 
of COL4A5, the gene located on chromosome Xq22 that codes for the α5-chainof type IV 
collagen. Autosomal-recessive inheritance occurs in perhaps 15% of cases, and autoso-
mal-dominant inheritance has been shown in a few cases with associated thrombocy-
topathy and in rare cases without platelet defects [15]. The disease initially manifests as 
asymptomatic microscopic haematuria, sometimes with superimposed episodes of gross 
haematuria. Progressively worsening proteinuria and end stage renal disease (ESRD) 
may eventually develop, although the rate of progression is quite variable [15].
Affected individuals have bilateral high-frequency sensorineural hearing loss 
[15]. Nonetheless, some affected individuals with the X-linked nephritis progress-
ing to ESRD may be without hearing loss, an occurrence which might lead to missed 
diagnosis.
In Alport’s syndrome, the similarities in connective tissue structure (collagen 
type IV) between basement membranes of glomeruli and the stria vascularis of the 
inner ear account for the affectation of both organs in most cases [15, 16].
2.1.1.2 Branchio-Oto-renal (BOR) syndrome
In Branchio-Oto-Renal (BOR) syndrome, there is concurrent occurrence of 
ear and renal abnormalities. Renal abnormalities include bilateral renal agenesis, 
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bilateral hypoplasia or dysplasia, unilateral renal agenesis with contralateral 
hypoplasia or dysplasia, ureteropelvic obstruction, and vesicoureteric reflux. Renal 
function ranges from normal to severe reduction in glomerular filtration rate [17]. 
The ear abnormalities range from preauricular pits, malformations in the external, 
middle, and inner ear; and hearing loss [7, 17].
2.1.1.3 ClC-K in renal salt loss and deafness (Bartter syndrome type IV)
ClC-Kb/barttin (see Figure 1) is mainly expressed in basolateral membranes of 
the thick ascending limb of Henle’s loop, where it is involved in the reabsorption 
of salt and, consequently, water [18]. In this part of the nephron, the Na + elec-
trochemical gradient (created by basolateral Na+/K+ pump) drives the secondary 
active transport of NKCC2 (present in the apical membrane), accumulating Na+, 
Cl−, and K+ into the cell. K+ is extruded back to the lumen through ROMK K+ 
channels (also present in the apical membrane), whereas Na + and Cl − are reab-
sorbed by the interstitial fluid through the Na+/K+ pump and ClC-Kb channels, 
respectively. Thus, the end product of this system is the reabsorption of NaCl into 
the blood stream (Figure 1A). In the inner ear, both ClC-K isomers are expressed in 
the basolateral membrane of marginal cells of the stria vascularis. This multilayered 
epithelium is responsible for both the high concentration of K+ and the positive 
potential (about 100 mV higher than normal extracellular fluids) of the endolymph 
of the scala media, both of which are important properties for hearing. In marginal 
cells—the more apical layer in the stria vascularis—Na+/K+ pumps and NKCC1 
transporters build up K+ and Cl − inside the cells. ClC-K/barttin channels recycle 
Cl − back to the interstitial fluid, while apical KCNQ1/KCNE1 K+ channels secrete 
the excess of potassium ions into the endolymph (Figure 1B) [19]. In agreement 
with the transport models involving ClCK/barttin channels, mutations in the gene 
encoding ClC-Kb cause salt-losing Bartter syndrome type III [20], characterized 
by hypokalemia, metabolic alkalosis and secondary hyperaldosteronism with 
normal or low blood pressure [21]. Mutations in the gene encoding barttin cause 
Bartter syndrome type IV that combines the salt wasting with congenital deafness, 
since both ClC-K proteins are non-functional in the absence of barttin [22]. When 
disruption occurs in only one of the ClC-K channels, as it does in ClCKb mutations 
in Bartter type III, hearing is preserved; the other isomer channel still provides the 
necessary Cl − recycling. Deafness occurs only on disruption of both ClC-K chan-
nels or upon disruption of barttin [22, 23].
2.2 Medication toxic effect
Over 450 medicines are reported to be ototoxic [24]. These include both pre-
scription medicines such as antibiotics, cancer medications, anti-malarias, and 
diuretics; and over-the counter medicines such as Non-Steroidal Anti-Inflammatory 
drugs (Pain killers). In most cases, this type of ototoxicity is an acute, short-lived 
side effect; if the patient stops taking the medication, the symptoms typically 
recede [24]. This is not the case, however, for aminoglycoside antibiotics and 
platinum derivatives used as cancer drugs which may be associated with permanent 
hearing loss [25]. The mechanism of drug-induced ototoxicity is varied.
2.2.1 Aminoglycoside antibiotics and high-ceiling diuretics
For the patient with CKD, the medications of importance in causing ototoxic-
ity are the aminoglycoside antibiotics, used commonly in treating urinary tract 
infections and septicaemia which are quite frequent in such patients and also 
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furosemide; a high-ceiling diuretic commonly used in treating fluid overload and 
pulmonary oedema in CKD patients. Though the ototoxic effect of aminoglycoside 
is known among many medical practitioners, the lack of diagnostic facilities in 
many centers across the world lead to the neglect of full assessment for this poten-
tial side effect. Lack of treatment interventions for hearing loss in many regions 
take away the interest in evaluation for this side effect.
The ototoxicity of furosemide is often overlooked by physicians and nurses. 
Furosemide toxicity commonly occurs when the medicine is administered as 
intravenous push medication and in a faster fashion.
2.3 Hearing loss among hemodialysis patients
Chronic kidney disease patients in End stage who are on hemodialysis are 
another cohort of CKD patient who suffer from hearing loss.
Several reports indicate that sensorineural hearing loss (SNHL) is considerably 
more prevalent in patients with chronic renal failure (CRF) than in the general 
population. It ranges from 28% to 77% [26, 27].
Although all frequencies can be affected by CRF, hearing impairment at high 
frequencies is most common [28]. In addition to antigenic similarity [29], the 
cochlea and kidney have similar physiological mechanisms, namely, the active 
transport of fluid and electrolytes achieved by the stria vascularis in the cochlea and 
the glomeruli in the kidney [3].
It was previously confirmed that the cochlea is affected by the systemic 
metabolic, hydroelectrolytic, and hormonal alterations that are associated with 
CRF [30].
Several variables may contribute to the etiopathogenetic mechanisms of hearing 
loss in CRF including factors related to the severity and duration of the disease, 
electrolyte disturbances, ototoxic drugs, age, comorbid conditions such as diabetes 
mellitus and hypertension, and hemodialysis [31–33].
In an Iraqi study by Haider K et al. to determine the effect of hemodialysis on the 
hearing threshold in patients with chronic renal failure (CRF), 59 patients were fol-
lowed up for 1 year with a pure-tone audiometric examination every 6 months [34]. 
At the beginning of the study, 39 patients (66.1%) had sensorineural hearing loss 
(SNHL). During the 12-month follow-up, 6 more patients developed SNHL giving 
a point prevalence rate of 76.3% at the end of the study. The hearing loss was more 
evident in the higher frequencies. Of the studied patients, 64.4% showed deteriora-
tion of the hearing threshold. The mean hearing threshold at the beginning of the 
study was 29.2 ± 21.1 dB versus 36.9 ± 17.3 dB at the end of the study (P < 0.001). No 
significant relation was found between age, sex, serum electrolytes, blood urea, and 
duration of CRF and hearing loss. Multivariate analysis showed that the duration of 
hemodialysis was the only significant independent predictor of SNHL [34].
3. Preventive healthcare strategies of sensorineural hearing loss
Because of the global burden of patients receiving chronic hemodialysis therapy, 
coupled with the high prevalence of hearing loss among this cohort which are often 
overlooked [26, 27], it is proper to highlight on the need to create awareness on pre-
ventive measures of hearing loss. Also, worldwide, 120 million people are estimated 
to be suffering from disabling hearing loss (>40 dB, average 0.5–4 KHz) [35]. 
Primary preventive measures should include genetic counseling targeted at families 
known to carry diseased genes. In the prenatal period, efforts should be made to 
address maternal problems like premature deliveries, and low birth weight through 
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improved antenatal care services. Perinatal/neonatal asphyxias, neonatal jaundices 
which requires exchange transfusions, neonatal meningitis etc. should be keenly 
addressed. There should be intensification of immunization programmes particu-
larly those against meningitis, measles, mumps and rubella in selected populations.
There should be careful and judicious use of ototoxic drugs such as furosemide 
and aminoglycoside antibiotics in the clinical settings, avoiding combination of the 
two groups where possible. There should be education on the risk of self-medications, 
use of herbal products that may be both ototoxic and nephrotoxic.
Education on overcrowding in the daycare centers, poor housing systems, bottle 
feeding, malnutrition etc.
There should be better management of acute respiratory infections, noise 
control and the appropriate use of hearing protection. Education of individuals, 
communities and governments is an essential prerequisite to implementation [35].
Neonatal/early childhood hearing screening should be instituted for early 
identification, diagnosis, treatment and rehabilitation of high-risk patients.
There should be early identification and management of comorbidities like 
hypertension and diabetes in the adult population.
Among the dialysis population, awareness must be created and screening 
programmes instituted where possible.
Above all, rehabilitation programmes for affected individuals should be imple-
mented to improve the quality of life of such individuals through the use of hearing 
aid and implants.
4. Conclusions
Hearing loss is not uncommonly associated with chronic kidney disease yet this 
co-morbidity is often overlooked by Health Care givers. The aetiopathogenesis of 
hearing loss in CKD patients are multifactorial; from genetic mutations that affect 
both the kidney and the inner ear due to similarities in structural proteins, through 
ototoxic medications commonly used in CKD patients, to the toxic effect of urae-
mia. It is hoped that this neglected aspect of care for patients with chronic kidney 
disease will receive the needed attention for holistic care of the CKD patient.
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